Back to Journals » Clinical Ophthalmology » Volume 7
Subtenon triamcinolone injection for postoperative cystoid macular edema associated with tafluprost
Authors Matsuura K , Uotani R, Terasaka Y
Received 31 May 2013
Accepted for publication 17 June 2013
Published 24 July 2013 Volume 2013:7 Pages 1525—1528
DOI https://doi.org/10.2147/OPTH.S49226
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Kazuki Matsuura,1 Ryu Uotani,2 Yuki Terasaka1
1Nojima Hospital, Tottori, Japan; 2Tottori University, Tottori, Japan
Purpose: We report the successful treatment of a case of cystoid macular edema (CME) associated with topical tafluprost, which was accompanied by serous retinal detachment (SRD).
Case: A 78-year-old woman underwent intraocular lens suture surgery, including anterior vitreous cutting, for crystalline lens dislocation in the right eye. Tafluprost was initiated 12 weeks after surgery. Intraocular pressure (IOP) was controlled at 10–14 mmHg. Visual acuity remained at 20/40–30/40. However, the patient complained of blurred vision (20/200) 9 months after surgery. CME accompanied by SRD was identified by optical coherence tomography (OCT) and treated with subtenon triamcinolone injection. Visual acuity rapidly increased to 20/50, and the volume of SRD decreased in a few days. Discontinuation of tafluprost and initiation of diclofenac eye drops improved visual acuity to 20/40 and resulted in improved OCT findings within a few weeks. Three months after injection, tafluprost was resumed along with diclofenac. No recurrence of CME occurred over the following 3 months, and IOP was controlled at 10–15 mmHg.
Conclusion: SRD is considered to be a symptom of treatment-resistant CME, which may lead to poor visual acuity after recovery. In such cases, subtenon triamcinolone injection should be strongly considered at an early stage.
Keywords: tafluprost, cystoid macular edema, serous retinal detachment, subtenon triamcinolone
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.